Abstract 2129P
Background
Exercise in cancer patients can mitigate declines in physical and psychosocial function. However, low recruitment and retention for in-person exercise programs limit evidence-based program development for patients with advanced lung cancer. The study of a virtual intervention, that leverages on the emerging acceptance of virtual healthcare delivery, has the potential to overcome barriers of prior exercise studies.
Methods
Mitigation of decline with Virtual Exercise with Lung Cancer is an ongoing prospective single-arm feasibility study. Individuals with advanced lung cancer on systemic therapy were recruited to a 12-week virtual group exercise program, including aerobic and functional strength exercises, delivered twice weekly over Zoom by an exercise physiologist. Feasibility measures included accrual, attendance, exercise adherence, attrition, and adverse events. Efficacy measures and quality of life (QoL) were assessed at start and end of program. Patient demographics, treatment, and outcomes were collected via electronic medical records.
Results
Of 44 patients referred, 30 were eligible and enrolled, of which, 3 were lost to follow up, 1 withdrew, 16 completed and 10 continue to participate in the program. Baseline demographics of 26 active participants: median age 65.5 years old (range 39 – 88), female (n=12), ECOG 0/1 (n=24), adenocarcinoma (n=21), metastasis to brain (n=9), liver (n=4), bone (n=7), and on targeted therapy (n=19). Total attendance is 87% and adherence is 96%. Of those who completed the program, statistically significant changes in physical function were identified by the 6 minute walk test (median improvement of 147 meters p = 0.046), gait speed (p = 0.030), sit to stand (p = 0.004), and biceps curl repetitions (p = 0.001). No significant difference was found in QoL using the Functional Assessment of Chronic Illness Therapy-Lung (FACT-L) and -Fatigue (FACT-F) questionnaires. Participants found the program to be accessible and were very likely to recommend this program to a friend.
Conclusions
Preliminary results suggest that a virtual exercise program for patients with advanced lung cancer is feasible, with high attendance and adherence, and significant improvements in physical function.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
Y. Wang, K. Campbell.
Funding
BC Lung Foundation, BC Cancer Foundation.
Disclosure
Y. Wang: Financial Interests, Personal, Advisory Board: BMS, AstraZeneca, Merck, Takeda; Financial Interests, Institutional, Research Grant: AZ. P. Camp: Financial Interests, Other, Personal, Conducted evaluation: Carrier Sekani Family Services. Financial Interests, Coordinating PI, Institutional, Receive funding for operational and team grants: Canadian Institutes of Health Research. Financial Interests, Coordinating PI, Institutional, Receive funding for operating grants: BC Lung Foundation. J. Laskin: Financial Interests, Advisory Board, Personal, invited speaker: Roche Canada. Financial Interests, Invited Speaker, Personal, speaker at educational event: Pfizer. Financial Interests, Advisory Board, Personal, invited to national ad board: Takeda. Financial Interests, Research Grant, Institutional, Funding for a IIT: Roche Canada. K. Campbell: Financial Interests, Personal, Stocks/Shares: Abcellera; Financial Interests, Personal, Speaker, Consultant, Advisor: Pfizer Canada. All other authors have declared no conflicts of interest.
Resources from the same session
2028TiP - Phase I, non-randomised, open-label, multi-centre dose escalation trial of BI 764532 (DLL3/CD3 IgG-like T cell engager [TcE]) + ezabenlimab (anti-PD-1 antibody) in patients (pts) with small cell lung cancer (SCLC) and other neuroendocrine carcinomas (NECs) expressing DLL3
Presenter: Julien Mazieres
Session: Poster session 06
2029TiP - Phase I study of ABBV-706, an anti-SEZ6 antibody-drug conjugate, alone or in combination in adults with advanced solid tumors
Presenter: Sreenivasa Chandana
Session: Poster session 06
2035P - Routine biomarker monitoring does not replace comprehensive clinical assessment in the detection of immunotherapy induced myocarditis
Presenter: Alexandra Johnson
Session: Poster session 06
2036P - Prevalence and risk evaluation of cardiovascular disease among newly diagnosed prostate cancer population in China
Presenter: Weiyu Zhang
Session: Poster session 06
2037P - Prehabilitation as a strategy to improve postoperative outcomes in frail cancer patients undergoing elective surgery: A systematic review and meta-analysis
Presenter: Muhammed Elfaituri
Session: Poster session 06
2039P - Primary endpoints of confirmatory randomized controlled trials for older patients with cancer: A scoping review
Presenter: Tomonori Mizutani
Session: Poster session 06
2041P - The prevalence of hematologic adverse events (HAEs) and myelodysplastic syndrome/acute myeloid leukemia (MDS/AML) in patients (pts) with advanced high grade ovarian carcinoma (aHGOC) receiving PARP inhibitor (PARPi), with or without a germline BRCA pathogenic variant
Presenter: Carmine Valenza
Session: Poster session 06
2042P - Improving breast cancer outcomes for indigenous women
Presenter: Vita Christie
Session: Poster session 06
2043P - Can Charlson Comorbidity Index (CCI) and Clinical Frailty Scale (CFS) assessments predict survival in octogenarians with colorectal cancer?
Presenter: Neda Nikolic
Session: Poster session 06
2044P - Bloodstream infections (BSI) in cancer patients: Epidemiology, antibiotic therapy and risk factors related to mortality
Presenter: Carlos López Jiménez
Session: Poster session 06